---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-22-002410"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2022-06-21T23:59:59+00:00"
generated_at: "2026-06-25T00:22:21.607215+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Chemomab appoints Jill M. Quigley to board of directors

## Summary
- Jill M. Quigley appointed to Chemomab board and audit committee, effective June 16, 2022.
- Quigley brings 20+ years biotech experience, including COO of Passage Bio and CEO of Nutrinia.
- Board expands to seven directors; audit committee now includes Quigley as financial expert.
- Quigley also serves on Terns Pharmaceuticals board (TERN) and chairs its audit committee.

## SEC filing metadata
- accession: 0001178913-22-002410
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2022-06-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891322002410/0001178913-22-002410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891322002410/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-22-002410
- JSON: https://secwatch.observer/filing/0001178913-22-002410.json
- Plain text: https://secwatch.observer/filing/0001178913-22-002410.txt

## Key facts
- Executive change
  Jill M. Quigley was appointed as Director at Chemomab Therapeutics Ltd..
  - Action: appointed
  - Role: Director
  source text: appointed Jill M. Quigley to the Board and the audit committee of the Board (the “Audit Committee”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534248/000117891322002410/0001178913-22-002410-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.